EVE Health Group Reports Solid Growth and Asset Sales

EVE Health Group Limited (AU:EVE) has released an update.

EVE Health Group Limited reports a 3% year-over-year revenue growth for its Meluka Australia brand, reaching $2.1 million despite reduced marketing spend, alongside the successful sale of Jenbrook property and ongoing negotiations for the Robyndale property sale. The company also signals strong customer interest in its new probiotic powder supplement system and aims to unlock capital through divestment of tea tree assets to fuel future growth in the health and wellness sector.

For further insights into AU:EVE stock, check out TipRanks’ Stock Analysis page.